Basic Stugeron Information

• INN (International Nonproprietary Name): Cinnarizine.
• Brand Names Available In Australia: Not registered in public formulary.
• ATC Code: N07CA02 — designates cinnarizine as a nervous system drug, “Other nervous system drugs” (N07), and calcium channel blockers for vestibular disorders (CA02).
• Forms & Dosages: Oral tablet 25 mg most common; extended-release tablets in some markets; syrup/suspension in select regions.
• Manufacturers In Australia: Not specified; international manufacturers include Janssen Pharmaceuticals, STADA, Hasco, Biogaran, LEK, Gedeon Richter and regional generics.
• Registration Status In Australia: Not on public formulary; unregistered for PBS listing.
• OTC / Rx Classification: Mostly OTC in EU and UK for motion sickness; may require prescription in some countries or for specific indications.

Latest Research Highlights

Worried whether recent studies support using cinnarizine for travel or vertigo?

Recent reviews and pharmacovigilance summaries from 2022 to 2025 reinforce cinnarizine’s role for motion sickness and vestibular vertigo while noting limits in high‑quality randomised controlled trials from Australia.

International meta‑analyses show cinnarizine, commonly dosed at 25 mg, reduces motion sickness symptoms compared with placebo and often compares favourably to older antihistamines for nausea control, though effect sizes are modest and heterogeneous across trials.

Safety signal reviews emphasise extrapyramidal and parkinsonian side effects after prolonged use, especially in older adults, which aligns with regulatory advisories in other jurisdictions.

Australian‑specific research is sparse, with the drug not listed on PBS and few TGA local reports suggesting low domestic usage or importation.

Key research gaps include head‑to‑head trials versus meclizine and betahistine in Australian populations and pharmacogenetic work on CYP2D6 metabolism affecting cinnarizine levels.

Data highlights: cinnarizine efficacy in motion sickness is supported but variable; adverse events cluster around sedation and movement disorders with chronic use.

Clinical Effectiveness In Australia

Are Australians getting the same benefits from cinnarizine as patients overseas?

Local clinical effectiveness must be inferred from international data because cinnarizine is not registered on the public Australian formulary.

International practice supports short‑term use for motion sickness with a single 25 mg dose given about two hours before travel and longer courses for vestibular disorders at 25 mg three times daily.

Clinicians and pharmacists in Australia may encounter imported products or patient‑supplied Stugeron tablets, and TGA guidance suggests reporting adverse events via the Database of Adverse Event Notifications.

Real‑world effectiveness can differ between urban and rural settings due to access to alternatives such as meclizine and promethazine from national chains and community pharmacies.

Typical expected outcomes: acute use usually reduces nausea and dizziness for travel; chronic vestibular indications can give modest symptom improvement over weeks to months with regular reassessment.

Regimen‑to‑benefit snapshot: single pre‑travel 25 mg often helps nausea; 25 mg three times daily may reduce chronic vertigo frequency but requires monitoring for side effects.

Indications And Expanded Uses

What is cinnarizine actually used for beyond travel sickness?

Registered indications internationally include motion sickness and vestibular vertigo, with standard motion sickness dosing of 25 mg two hours before travel and vertigo dosing of 25 mg three times daily.

Off‑label uses sometimes reported include chronic microcirculatory cerebral disorders and adjunctive therapy for arteriosclerotic symptoms presenting with dizziness.

In Australia, off‑label prescribing demands clinical justification and informed consent because the medicine is not PBS‑listed.

Paediatric use is limited; the medicine is generally not recommended for children under five, and ages five to 12 use lower doses around 12.5 mg two to three times daily.

Definition list:

• Indications: Motion sickness; vestibular vertigo.
• Off‑label: Cerebral microcirculatory disorders; adjunctive vascular dizziness therapy.

Standard regimens by indication: motion sickness 25 mg pre‑travel, repeat every eight hours if required; vertigo 25 mg tds for several weeks with review.

Composition And Brand Landscape

Which products contain cinnarizine and how are they sold overseas?

Active ingredient: cinnarizine (INN) with ATC code N07CA02 as a vestibular calcium channel blocker.

The most common commercial strength is 25 mg oral tablets, and packaging ranges from blister packs of 10–50 to bulk boxes of 100 in some markets.

Major international brand names include Stugeron and generics from Janssen, STADA, Hasco, Biogaran, LEK and Gedeon Richter.

In Australia the medicine is not registered on the public formulary, so patients often import Stugeron or buy online from overseas suppliers.

Formulation table:

• Oral tablet: 25 mg — most common; manufacturers include Janssen and several generics.
• Extended‑release tablet: Rare; limited markets.
• Syrup/suspension: Available in select regions.

Importation considerations: check the supplier’s credentials, batch and expiry details, and follow TGA personal importation guidance where applicable.

Contraindications And Special Precautions

Who should not take cinnarizine and when should extra care be used?

Absolute contraindications include known allergy to cinnarizine or excipients, porphyria, severe hepatic impairment, and pregnancy and breastfeeding unless absolutely essential.

Relative contraindications requiring monitoring include Parkinson’s disease because cinnarizine may worsen motor symptoms, the elderly due to higher risk of drowsiness and extrapyramidal effects, and significant liver or kidney impairment.

Concomitant use with CNS depressants, including alcohol, increases sedation and risk of harm.

For Indigenous and remote populations, higher comorbidity prevalence and limited access to specialist review call for cautious prescribing and active monitoring.

Work and safety advice: avoid driving or operating heavy machinery until the effect on alertness is known.

Decision flow for high‑risk groups:

• Elderly: consider dose reduction and short duration; monitor for confusion or parkinsonian features.
• Pregnancy/Breastfeeding: avoid unless clinician assesses benefit outweighs risk.
• Neurodegenerative disease: prefer alternatives and consult neurologist where possible.

Dosage Guidelines

How should cinnarizine be dosed for different ages and conditions?

Standard adult dosing for motion sickness is 25 mg taken about two hours before travel, repeating every eight hours if necessary.

For vertigo and vestibular disorders the usual adult dose is 25 mg three times daily, with a total daily dose of 75 mg.

Children under five are not recommended to use cinnarizine, and children aged five to 12 typically receive 12.5 mg two to three times daily when indicated.

Elderly patients should start at reduced doses and be closely monitored for sedation and movement disorders.

Hepatic impairment calls for dose reduction or avoidance, noting primary hepatic metabolism with CYP2D6 involvement.

Typical durations: single short course for travel; several weeks to months for chronic vestibular therapy with periodic review.

Checklist for dose adjustments:

• Liver disease: reduce dose or avoid due to hepatic metabolism.
• Elderly: lower starting dose and short treatment duration.
• Interacting medicines: review concomitant CYP2D6 substrates or inhibitors.

Interactions Overview

Which medicines, foods or substances can affect cinnarizine or be affected by it?

Major interaction concerns are enhanced CNS depression with alcohol and other sedatives, and additive anticholinergic effects with some antihistamines and antipsychotics.

CYP interactions may alter cinnarizine levels because hepatic metabolism, including CYP2D6, plays a role in clearance.

Avoid concurrent use with drugs that exacerbate extrapyramidal symptoms such as typical antipsychotics and metoclopramide.

Food interactions are minimal, but alcohol notably potentiates drowsiness and should be avoided while taking the medicine.

Pharmacist checks: screen for sedative co‑medications, antipsychotics, strong CYP2D6 inhibitors and recent importation of overseas formulations to ensure correct product identity.

Cultural Perceptions And Patient Habits In Australia

How do Australians typically approach travel‑sickness medicines like Stugeron?

Australian patients tend to be price sensitive and reliant on PBS subsidies when available, which makes non‑PBS options less popular.

Because cinnarizine is not PBS‑listed, many Australians choose locally available, subsidised alternatives such as meclizine or promethazine or try herbal options like ginger tablets for mild symptoms.

Rural and remote patients may import Stugeron online because local stock can be limited, and telehealth prescriptions make access easier though they raise quality‑check concerns.

Patients often trust community pharmacists at Chemist Warehouse, Priceline and TerryWhite Chemmart for practical travel‑sickness advice and for guidance on safer non‑sedating options when driving or working outdoors.

Indigenous health settings require culturally safe conversations about risks, benefits and acceptable alternatives if cinnarizine is under consideration.

Urban versus rural preferences: urban patients more commonly accept pharmacist recommendations for PBS‑listed medicines, while rural patients report higher rates of online importation for specific overseas brands.

Availability And Pricing Patterns

Where can Australians source Stugeron and what will it cost?

Availability in Australia is limited because Stugeron is not registered on the public formulary, so it is not PBS subsidised and not commonly stocked by national wholesalers.

Some pharmacies may hold small imported supplies and many patients source the medicine from overseas online pharmacies or personal importation pathways.

Pricing varies widely without PBS subsidy, with cheaper generics imported from overseas being less expensive but carrying quality and regulatory uncertainty.

Major Australian chains typically prefer PBS‑listed alternatives and commonly stock meclizine, hyoscine and promethazine instead of cinnarizine.

Telehealth services can prescribe alternatives and document imported medicines in My Health Record for continuity of care.

Safe online purchase checklist: confirm the supplier’s licence, check batch numbers and expiry dates, and be cautious with unbranded or unusually cheap suppliers.

Note: in the online pharmacy context, Stugeron is available without a prescription with discreet delivery to Australia in 5‑14 days.

Comparable Medicines And Patient Preferences

Which medicines are commonly chosen instead of cinnarizine and why?

Common Australian alternatives include meclizine, dimenhydrinate, promethazine, hyoscine (scopolamine) and betahistine for vestibular symptoms.

Pros of cinnarizine include effectiveness for certain vestibular symptoms and tolerability in short‑term use.

Cons include sedating effects and risk of extrapyramidal symptoms with prolonged therapy, and the lack of PBS listing complicates access and cost.

Meclizine and promethazine are widely available and often PBS‑subsidised or cheaper, which influences patient and pharmacist preference for acute travel sickness.

Betahistine is used for Ménière’s disease but has a different efficacy profile compared with cinnarizine.

Clinician checklist when choosing therapy: consider whether the need is acute travel or chronic vertigo, patient age, comorbidities, employment involving driving, and local availability and cost.

FAQ

Can I buy Stugeron in Australia?

Not commonly via PBS; patients may import Stugeron or find small pharmacy stocks, and it is important to check TGA personal importation rules and product authenticity.

Is cinnarizine safe for elderly relatives?

Use caution because of increased risk of drowsiness, falls and parkinsonism; dose reduction and close monitoring are recommended.

Can I drive after taking cinnarizine?

Avoid driving or operating machinery until you know how the medicine affects your alertness due to sedation risk.

What if I miss a dose?

Take the missed dose when remembered unless it is close to the next scheduled dose; do not double up on doses.

If in doubt, consult a pharmacist for personalised advice and report any adverse events to the TGA via the Database of Adverse Event Notifications.

Guidelines For Proper Use And Pharmacist Counselling

What should a pharmacist tell a customer asking about Stugeron or cinnarizine?

Confirm the product identity as cinnarizine 25 mg and advise the correct pre‑travel dose of 25 mg about two hours before departure, repeating every eight hours only if needed.

Warn about sedation and the need to avoid alcohol while taking the medicine.

Discuss cheaper or PBS alternatives if cost or access is an issue and document any imported medicine in the patient’s medication history.

Report adverse events to the TGA and ensure that telehealth‑prescribed alternatives are recorded in My Health Record when possible.

Counselling for high‑risk groups: for elderly patients emphasise fall risk and signs of extrapyramidal effects; for pregnant or breastfeeding customers advise avoidance unless a prescriber recommends otherwise.

Storage advice: keep in a cool, dry place at room temperature away from children.

Counselling checklist mapping:

• Drivers/workers: emphasise sedation risk and alternative choices.
• Elders: recommend dose reduction and monitoring.
• Paediatrics: clarify age limits and correct lower dosing for 5–12 year olds.

Delivery Across Australia